MONROVIA, Calif., June 19, 2013 (GLOBE NEWSWIRE) -- Immunotech Laboratories, Inc. (Pink Sheets:IMMB) today announced the results from Gap Analysis report.

Immnuotech President Harry Zhabilov and Vice President of business development Blaine Nabors announced the results from the Gap Analysis report. This report is the first step in the moving towards FDA clinical trials for Immunotech Laboratories.

IND Directions' Dr. Patricia Williams has conducted a gap analysis with the objective of identifying areas that require more information on IPF for the Pre-IND and IND submissions to FDA. The materials reviewed included general product technology overviews, meeting abstract, technical information on the peptide structure and manufacturing, and a protocol for a pilot clinical trial conducted in Mexico.   

Dr. Williams reports that Zhabilov's IPF platform proposed mechanism of action represents a novel approach for the treatment of HIV via inhibition of HIV infection (i.e. blocking attachment and entry into T-cells) and stimulating cell-mediated immunity. Additional studies in cell culture and in animals were recommended to further document IPF's mechanism of action and efficacy against HIV.

Zhabilov and Mr. Nabors stated that Immunotech Laboratories is now preparing for the Pre-IND studies that will begin by the end of this year and be subsequently presented to the FDA. Mr. Nabors said "We strive to provide further advancements of Immunotech Inactivated Pepsin Fraction "IPF" 

About Immunotech Laboratories

Immunotech Laboratories is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases such as HIV and AIDS. www.immunotechlab.com

Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Immunotech Laboratories or any other person that the objectives and plans of Immunotech Laboratories will be achieved should not regard the forward-looking statements as a representation.